Nursing team at the Novavax study at Oldham Leisure Centre

Significant role for NCA as Novavax announces Covid-19 vaccine is 89.3% effective

The  Novavax Covid-19 vaccine is 89.3% effective at preventing Covid-19, a study supported by the Northern Care Alliance NHS Group has shown.

This is according to the interim analysis of Phase III study data, including effectiveness against the new variants of concern. Nearly 500 volunteers took part in the study through the NCA.

The  NIHR-supported Novavax study is the largest ever double blind, placebo-controlled trial to be undertaken in the UK. It recruited over 15,000 participants from 35 research UK sites in just over two months. It was the first phase 3 study for the US-based biotechnology firm Novavax’s  vaccine anywhere in the world.

In Greater Manchester, the study has been carried out by local research teams at two community sites. The NCA recruited 480 participants who were vaccinated at Oldham Leisure Centre and Stockport NHS Foundation Trust recruited 762. Greater Manchester was the highest recruiting region in the country.

Both sites worked in collaboration with the National Institute for Health Research (NIHR) Clinical Research Network Greater Manchester, and NHS staff from other local trusts were part of the teams which delivered the study.

The interim efficacy data and safety data will be submitted to all regulators across the world – including the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK – for independent scrutiny and product approval.

A significant proportion of participants taking part in the study were recruited through the NHS Covid-19 Vaccine Research Registry – an online registry of over 390,000 people, including 20,000 in Greater Manchester, who have signed-up to be contacted about taking part in Covid-19 vaccine studies. More than 25 percent of enrollees in the trial were over the age of 65, while a large proportion of volunteers had underlying medical conditions generally representative of the population.

The UK phase 3 trial is a randomised, placebo-controlled, observer-blinded trial during which 50% of volunteers were given two intramuscular injections of the vaccine candidate, 21 days apart, while the remaining received a placebo.

The UK Vaccines Taskforce and National Institute for Health Research (NIHR) Clinical Research Network have played vital roles in the rapid recruitment and enrollment of volunteers.

Professor Andy Ustianowski, Deputy Clinical Director at NIHR Clinical Research Network Greater Manchester, and NIHR joint national Specialty Lead for Infection, said: “These results are fantastic and something Greater Manchester’s NHS research community – and the amazing trial participants – can proudly say they have played a big part in.

“This huge research project has been made possible thanks to a “One Greater Manchester” approach which involved colleagues from across various NHS organisations working together to ensure local communities had the opportunity to be part of this groundbreaking research. We sincerely thank all the staff and participants whose contribution should now benefit so many people.”

Professor Phil Kalra, Principal Investigator for the trial at the NCA , said: “Our team has worked incredibly hard to undertake the Novavax trial and we are thrilled to learn of these findings which show such a high degree of effectiveness.

“We are proud that the Northern Care Alliance, with support from our research colleagues in Greater Manchester, has made a real contribution to this marvellous achievement and we are extremely grateful for the efforts of all our staff and, of course, the volunteers who stepped forward to be part of this vital research.”

The UK public can continue to support the national effort to speed up vaccine research and receive more information about volunteering for future vaccine studies by visiting www.nhs.uk/researchcontact.

The UK government has already secured 60 million doses of the Novavax NVX-CoV2373 vaccine. Provided it meets standards on safety, effectiveness and quality following publication of results, the vaccine will be manufactured using FUJIFILM Diosynth Biotechnologies’s facilities in Billingham, Stockton-on-Tees.